Panome Bio and TD2 Oncology expand their collaboration to interlink translational oncology with advanced multi-omics profiling, enhancing cancer research and drug development.

Panome Bio and Audubon Bioscience have joined forces to enhance cancer research through innovative FFPE biospecimen and metabolomics solutions.

Panome Bio has launched an exposomics platform, offering groundbreaking chemical exposure profiling services essential for disease research.

Panome Bio unveils MassID™, a transformative platform enhancing metabolomics data analysis, paving the way for significant biotech advancements.

Panome Bio has introduced a groundbreaking metabolomics workflow for FFPE samples, enhancing clinical discovery and transforming data analysis in research.

Panome Bio has successfully obtained CLIA certification for its advanced laboratory, enhancing its capabilities in clinical laboratory testing and multi-omics services.

Panome Bio, renowned for its multi-omic services, introduces transcriptomics to its suite, enhancing biological analysis for researchers.

Panome Bio introduces a global phosphoproteomics platform, revolutionizing multi-omic discovery solutions and advancing disease research.

Panome Bio has appointed Jean-Pierre Wery to its Board of Directors, setting the stage for significant growth in 2025 as the company expands its operations.